Application DetailsWestern Blotting (WB). A concentration of 0.25-0.50 µg/mL is recommended for WB. Human AKT1 has a predicted length of 480 residues and MW of 56 kDa. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
TargetRAC-alpha serine/threonine-protein kinase
SpecificityThe specificity of this antibody has been confirmed by WB against the antigen. Human; mouse; rat; chicken;
Target Host SpeciesHuman
Species ReactivityChicken, Human, Mouse, Rat
Immunogen DescriptionA synthetic peptide (VDSERRPHFPQFSYSAS) corresponding to a region (461-477) from human RAC-alpha serine/threonine-protein kinase.
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute in 1 mL of sterile-filtered PBS (pH 7.4) to achieve an antibody concentration of 100 µg/mL. Centrifuge to remove any insoluble material.
Storage InstructionsAt least 12 months after purchase at 2-8°C (lyophilized formulations). After reconstitution, aliquot and store at -20°C for a higher stability. Avoid freeze-thaw cycles.
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesProtein kinase B alpha; 184.108.40.206; RAC-PK-alpha; PKB; C-AKT; AKT1; RAC;
Scientific BackgroundThe protein kinase AKT has a role in glucose transport, glycogen synthesis, inhibiting apoptosis, cell-cycle progression, cell growth and cancer. Three isoforms of the AKT gene have been identified; AKT1, AKT2 and AKT3. AKT1 or RAC-alpha serine/threonine-protein kinase is activated by insulin and various growth and factors.